Catalyst Pharmaceuticals (CPRX) Stock Price
Catalyst Pharmaceuticals Price
Revenue has compounded at 60.5% per year over the past 15 years to 588.99 M USD. Earnings per share have grown at 33.4% per year over the last 6 years. Catalyst Pharmaceuticals's net margin stands at 36.4%, up from 28.0% several years earlier. Analysts set a median price target of 34.68 USD, implying 10.1% above the current price. Of 14 analysts, 13 rate the stock a buy — an overall Buy consensus.
Catalyst Pharmaceuticals stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Catalyst Pharmaceuticals business model & stock analysis
Frequently asked questions about Catalyst Pharmaceuticals
The business model of Catalyst Pharmaceuticals Inc is focused on the development and commercialization of innovative therapies for rare neurological disorders. Catalyst's mission is to improve the lives of patients by providing effective treatments. They leverage their expertise in drug development, clinical research, and regulatory affairs to identify, develop, and bring promising therapies to market. Catalyst aims to address unmet medical needs and provide hope to patients and their families. Through their dedication and commitment, Catalyst Pharmaceuticals Inc strives to make a positive impact in the field of rare disease therapeutics.
Catalyst Pharmaceuticals Inc is primarily active in the pharmaceutical industry.
The main competitors of Catalyst Pharmaceuticals Inc in the market are other pharmaceutical companies that specialize in the same therapeutic areas as Catalyst. These competitors include companies such as BioMarin Pharmaceutical Inc, Retrophin Inc, and Amicus Therapeutics Inc. These companies operate within the same industry and are engaged in the development and commercialization of treatments for rare diseases, similar to Catalyst Pharmaceuticals Inc. Enduring competition in the pharmaceutical market necessitates Catalyst to continuously innovate and differentiate itself to maintain a competitive edge and capture a larger market share.
Catalyst Pharmaceuticals Inc, founded in 2002, is a biopharmaceutical company specializing in the development of innovative therapies for rare neurological disorders. Headquartered in Coral Gables, Florida, Catalyst is dedicated to addressing unmet medical needs and improving the quality of life for patients. With a focus on orphan drug development and personalized medicine, Catalyst has been at the forefront of research and development in the rare disease space. The company is driven by a passionate team of professionals committed to making a meaningful impact in the lives of patients and their families. Catalyst Pharmaceuticals Inc has established itself as a leading player in the pharmaceutical industry, continuously striving towards breakthrough treatments.
Catalyst Pharmaceuticals Inc has achieved several significant milestones. The company received FDA approval for its drug Firdapse, which is used to treat Lambert-Eaton Myasthenic Syndrome (LEMS) in adults. This approval was a major achievement for Catalyst Pharmaceuticals Inc as it marked the first FDA-approved treatment for LEMS. The company also successfully completed a Phase 3 clinical trial for Firdapse, demonstrating its efficacy and safety. Furthermore, Catalyst Pharmaceuticals Inc has obtained Orphan Drug Designation from the FDA for Firdapse, providing the company with market exclusivity for the treatment of LEMS. These milestones showcase the company's dedication to developing innovative treatments and positioning itself as a leader in rare diseases.
Catalyst Pharmaceuticals Inc is primarily present in the United States.
Catalyst Pharmaceuticals Inc represents a commitment to excellence and innovation in the pharmaceutical industry. With a focus on developing and commercializing impactful medications, Catalyst aims to improve the quality of life for patients worldwide. The company's corporate philosophy centers around integrity, transparency, and a patient-centric approach. By employing cutting-edge research and collaboration with healthcare professionals, Catalyst strives to deliver groundbreaking therapies that address significant unmet medical needs. With a strong emphasis on scientific rigor and ethical practices, Catalyst Pharmaceuticals Inc demonstrates a dedication to providing effective and safe treatments to individuals suffering from various medical conditions.
Analysts currently set an average price target of 35.19 USD for the Catalyst Pharmaceuticals stock (median: 34.68 USD), implying +11.7 % versus the latest price. The consensus is based on 14 analyst ratings.
9 analysts currently rate the Catalyst Pharmaceuticals stock: 0 recommend buying, 6 holding and 3 selling. For 2026, analysts expect Catalyst Pharmaceuticals to generate revenue of 636.20 M USD and earnings per share of 3.07 USD.
Converted at the current exchange rate, the Catalyst Pharmaceuticals share trades at 28.24 EUR (31.49 USD).
The Catalyst Pharmaceuticals share (CPRX) is listed on 5 stock exchanges, including: NASDAQ (CPRX), SIX (Zürich) (CN2.SW), Frankfurt (CN2.F), München (CN2.MU), Düsseldorf (CN2.DU).
Catalyst Pharmaceuticals Inc is a US biopharmaceutical company that focuses on the development and marketing of drugs for rare diseases. The company was founded in 2002 and is headquartered in Coral Gables, Florida.
The expected revenue of Catalyst Pharmaceuticals is 636.20 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Catalyst Pharmaceuticals is 390.13 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Catalyst Pharmaceuticals is currently 10.27. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Catalyst Pharmaceuticals stock.
The price-to-sales ratio (P/S) of Catalyst Pharmaceuticals is currently 6.30. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Catalyst Pharmaceuticals stock.
The Eulerpool Quality Score for Catalyst Pharmaceuticals is 6/10.
The ISIN of Catalyst Pharmaceuticals is US14888U1016. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Catalyst Pharmaceuticals is A0LCUL. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Catalyst Pharmaceuticals is CPRX. The ticker symbol is used to trade Catalyst Pharmaceuticals shares on the stock exchange.
Catalyst Pharmaceuticals stock
Catalyst Pharmaceuticals Peer Group
Catalyst Pharmaceuticals Ticker
Catalyst Pharmaceuticals FIGI
All fundamentals and in-depth analysis of Catalyst Pharmaceuticals
Our stock analysis for Catalyst Pharmaceuticals stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Catalyst Pharmaceuticals. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.